Jon has said repeatedly that the 4 NNZ-2591 indications currently in Ph 2 are worth 5x the market of Trof. If you value Trof at US$27, then NNZ-2591 is potentially worth US$135 a share, or AU$200 a share. So for NNZ-2591 to be worth $2.50 now as you suggest means applying a 99% discount to NNZ-2591. That sounds a little steep considering the average orphan drug Ph 1 to approval success rate is 25% (75%) discount.And I'm puzzled why the potential for Fragile X, Alzheimer’s, Parkinsons, multiple sclerosis, traumatic brain injury, stroke and autism (all diseases Neuren has either patents for or has discussed treating are still worth $zero.To me Trof and Retts main significance is validating the potential of what Jon has made clear he believes is Neurens most valuable asset - NNZ-2591.
Surely Neurens most valuable asset is worth more than $2.50 a share?
Jon has said repeatedly that the 4 NNZ-2591 indications...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.02 |
Change
-1.250(6.17%) |
Mkt cap ! $2.428B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $18.82 | $19.92M | 1.034M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1652 | $19.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.03 | 11612 | 4 |
View Market Depth
| Last trade - 16.10pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.10 |
Change
-1.250 ( 6.19 %) |
||||
| Open | High | Low | Volume | ||
| $20.39 | $20.46 | $18.83 | 299764 | ||
| Last updated 15.59pm 04/06/2024 ? | |||||
| NEU (ASX) Chart |